Cargando…

Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic enzyme that regulates blood cholesterol levels by degrading low-density lipoprotein (LDL) receptors from the surface of hepatocytes. Studies have shown that inhibiting this molecule decreases the cardiovascular risk in individuals wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabih, Ahmad M, Niaj, Ahmad, Raman, Aishwarya, Uprety, Manish, Calero, Maria Jose, Villanueva, Maria Resah B, Joshaghani, Narges, Villa, Nicole, Badla, Omar, Goit, Raman, Saddik, Samia E, Dawood, Sarah N, Mohammed, Lubna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990958/ https://www.ncbi.nlm.nih.gov/pubmed/36895542 http://dx.doi.org/10.7759/cureus.34648

Ejemplares similares

Risk of Stroke in Migrainous Women, a Hidden Association: A Systematic Review
por: Saddik, Samia E, et al.
Publicado: (2022)

Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review
por: Dawood, Sarah N, et al.
Publicado: (2022)

Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review
por: Villanueva, Maria Resah B, et al.
Publicado: (2022)

Bempedoic Acid’s Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review
por: Goit, Raman, et al.
Publicado: (2022)

The Multidisciplinary Management of Perianal Fistulas in Crohn’s Disease: A Systematic Review
por: Badla, Omar, et al.
Publicado: (2022)

The Role of Leptin in Systemic Lupus Erythematosus: Is It Still a Mystery?
por: Villa, Nicole, et al.
Publicado: (2022)

Fertility and Pregnancy Outcomes in Patients With Adenomyosis: Is Adenomyosis Synonymous With Infertility?
por: Calero, Maria Jose, et al.
Publicado: (2022)

How Residing in a Long-Term Care Facility Affects Suicidal Risk in Patients With Dementia: A Systematic Review
por: Joshaghani, Narges, et al.
Publicado: (2022)

A Systematic Review Comparing Digital Subtraction Angiogram With Magnetic Resonance Angiogram Studies in Demonstrating the Angioarchitecture of Cerebral Arteriovenous Malformations
por: Raman, Aishwarya, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022)

Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022)

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
por: Suur, Bianca E., et al.
Publicado: (2022)

Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
por: Shafiq, Muhammad, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
por: Jang, Hyun-Duk, et al.
Publicado: (2020)

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR
por: Wang, Yan, et al.
Publicado: (2012)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
por: Gu, Hong-mei, et al.
Publicado: (2015)

The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
por: Kim, Eun Ji, et al.
Publicado: (2020)

Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease
por: Chiang, Shih-Min, et al.
Publicado: (2019)

Corrigendum to: Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Publicado: (2021)

Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults
por: Gannagé-Yared, Marie-Hélène, et al.
Publicado: (2022)

Proprotein convertase subtilisin/kexin type 9: A new target molecule for gene therapy
por: Banaszewska, Anna, et al.
Publicado: (2012)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
por: O’Connell, Emma M., et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
por: Schlüter, Klaus-Dieter, et al.
Publicado: (2020)

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia
por: Peng, Yanren, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 6: A Risk Factor for Survival in Pulmonary Fibrosis?
por: Yang, Ivana V.
Publicado: (2023)

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
por: Lawler, Patrick R., et al.
Publicado: (2023)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
por: Rikhi, Rishi, et al.
Publicado: (2023)

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases
por: Ferri, Nicola
Publicado: (2012)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018)

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia
por: Li, Bin, et al.
Publicado: (2016)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
por: Duprez, Daniel A, et al.
Publicado: (2020)

Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
por: Cho, Kyung Hoon, et al.
Publicado: (2020)

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
por: Pickett, June K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vhvb4qdk54voecad04p4u52l7r